- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
VYGR
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Voyager Therapeutics Inc · Healthcare · Biotechnology
Latest close
3.03 USD
-2.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -18.9% below the Trend Line and sits at 5.5% of its 52-week range. The latest completed week returned -2.3%, after a -19.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.
Setup score
15
out of 100
Latest Close
3.03 USD
31 Jul 2026
1W Return
-2.3%
latest completed week
4W Return
-19.8%
short-term follow-through
12W Return
-25.2%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.3%
Latest completed week; four-week move -19.8%.
Indicator stack
17/24
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.74%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
52/100 conviction; expected move 19.8%.
News sentiment
52/100
59 relevant articles in the latest sentiment read.
Event risk
3d
Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -18.9% below the Trend Line and sits at 5.5% of its 52-week range. The latest completed week returned -2.3%, after a -19.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0312-week average 0.05
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -19.8% over four weeks, -25.2% over 12 weeks, and 2.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.22Latest activity-pressure read.
Pressure change-54.7%Four-week change in activity pressure.
Leadership-29.79Latest relative-leadership reading.
RS change-78.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value34/100Relative valuation strength. Underlying universe rank 67; rank 1 is best.
Quality1/100Profitability and accounting quality. Underlying universe rank 100; rank 1 is best.
Momentum26/100Medium-term price momentum. Underlying universe rank 75; rank 1 is best.
Growth11/100Revenue and earnings growth. Underlying universe rank 90; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 5.1x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -70.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -178.6% Gross profit retained from each unit of revenue.
- Operating margin
- -319.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -345.4% Free cash flow generated from revenue.
- Return on invested capital
- -53.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -45.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -1.6% Net share repurchases relative to market value.
- Shareholder yield
- -1.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
VYGR shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 19.8%, and Sharemaestro trend signal inactive.
Conviction52/100
Expected move19.8%
Put/call volume0.00
Insider activity9 / 0
9 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment52/100
Weighted news tone is neutral across 59 relevant articles.
15 positive · 33 neutral · 11 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move19.8%Nearest-chain priced movement where available.
52-week drawdown-45.4%Distance below the 52-week high.
13-week volatility6.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher11 of 2614 weeks finished lower.
Best week+17.5%Week of 27 Feb.
Worst week-14.0%Week of 5 Jun.
Latest week-2.3%Week of 31 Jul.
Shape of recent returns
Strong gains7
Modest gains4
Flat weeks1
Modest losses4
Sharp losses10
Recent vol6.4%13-week weekly-return volatility.
Base vol7.9%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew7.0% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape18/100
Trend, activity pressure, participation, and risk combine to a 18/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 44.74%Next-week expectancy is negative with a 44.74% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors15/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 78; Small Cap Core rank 73 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100VYGR shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 19.8%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 19.8% Sentiment52/100Weighted news tone is neutral across 59 relevant articles.
Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A Insiders9 / 09 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 3.03 USD | -2.3% | 3.73 USD | 5.67 USD | -1.22 | -29.79 | 2.6M | Off |
| 24 Jul 2026 | 3.10 USD | -2.2% | 3.77 USD | 5.71 USD | -0.88 | -27.99 | 3.4M | Off |
| 17 Jul 2026 | 3.17 USD | -7.8% | 3.80 USD | 5.75 USD | -0.60 | -27.81 | 4.1M | Off |
| 10 Jul 2026 | 3.44 USD | -9.0% | 3.83 USD | 5.79 USD | -0.64 | -25.20 | 4.3M | Off |
| 3 Jul 2026 | 3.78 USD | 5.3% | 3.86 USD | 5.83 USD | -0.79 | -16.71 | 2.7M | Off |
| 26 Jun 2026 | 3.59 USD | -3.5% | 3.88 USD | 5.87 USD | -1.07 | -20.33 | 4.5M | Off |
| 19 Jun 2026 | 3.72 USD | 6.3% | 3.89 USD | 5.92 USD | -0.93 | -21.24 | 1.8M | Off |
| 12 Jun 2026 | 3.50 USD | 5.1% | 3.91 USD | 5.97 USD | -0.53 | -24.07 | 2.5M | Off |
| 5 Jun 2026 | 3.33 USD | -14.0% | 3.92 USD | 6.03 USD | -0.20 | -26.40 | 2.8M | Off |
| 29 May 2026 | 3.87 USD | 1.8% | 3.95 USD | 6.09 USD | 0.25 | -18.80 | 1.8M | Off |
| 22 May 2026 | 3.80 USD | 0.9% | 3.98 USD | 6.14 USD | 0.17 | -17.98 | 3.8M | Off |
| 15 May 2026 | 3.77 USD | -7.0% | 4.01 USD | 6.20 USD | 0.07 | -17.86 | 3.0M | Off |
| 8 May 2026 | 4.05 USD | 7.7% | 4.05 USD | 6.26 USD | 0.15 | -12.20 | 2.7M | Off |
| 1 May 2026 | 3.76 USD | -0.8% | 4.08 USD | 6.30 USD | 0.05 | -14.21 | 1.7M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.